explore -WSS

explore

author：fashion 2025-09-29 18:59:36 - browse：5

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： STAT Wunderkinds: Ruey Hu's digital tools for parsing research

WSS

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Stroke deaths set to near 10 million globally by 2050

Readout Newsletter: XBI biotech index, Akero Therapeutics

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Emergency medicine has repudiated 'excited delirium.' Now what?

Emergency medicine has repudiated 'excited delirium.' Now what?

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Sana to lay off nearly a third of staff, de

At least 13 dead in Texas as scorching temps continue

Why age limits for politicians are a terrible idea

Apple is now the first public company to be valued at $3 trillion

VC firm General Catalyst wants to buy a health system

Supreme Court strikes down use of affirmative action

The future of health care in the House

Guidelines to prevent youth baseball injuries need more muscle

The future of health care in the House

hotspot

FDA has safety concerns on CRISPR

First Opinion Podcast: How to protect health care in times of war

Medtronic CEO on promising devices for diabetes, hypertension

Why age limits for politicians are a terrible idea

VC firm General Catalyst wants to buy a health system

The future of health care in the House

entertainment

entertainment

hotspot

Wikipedia